Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 8/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264005 | 0.89 | BACE1 (0.47) | BACE1NOS1MCHR1NR3C2NOS2 | |
| SCHEMBL23980701 | 0.73 | KDM4E (0.49) | NOS1MCHR1KDM4EALDH1A1HPGD | |
| SCHEMBL4937660 | 0.70 | BACE1 (0.73) | BACE1NOS1NOS2NOS3DHFR | |
| Ammonia Solution, Strong SCHEMBL4940874 | 0.69 | PDGFRB (0.44) | BACE1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29919905 | 0.69 | NQO1 (0.67) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8393507 | 0.69 | NQO1 (0.67) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29862025 | 0.67 | ALDH1A1 (0.59) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8391116 | 0.67 | ALDH1A1 (0.59) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5749415 | 0.67 | NQO1 (0.53) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4941238 | 0.67 | BACE1 (1.00) | BACE1NOS1NOS2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| CN-101124205-A | Substituted aminopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | CN | claimed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| CN-101124205-A | Substituted aminopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | CN | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | BACE1 30/4885NOS1 269/4885MCHR1 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.